The blockade of immune checkpoints in cancer immunotherapy
Top Cited Papers
- 22 March 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 12 (4), 252-264
- https://doi.org/10.1038/nrc3239
Abstract
No abstract availableKeywords
This publication has 117 references indexed in Scilit:
- Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptorCancer Immunology, Immunotherapy, 2011
- Active Immunotherapy Combined With Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone MiceMolecular Therapy, 2011
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signalNature Immunology, 2009
- Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+The Prostate, 2009
- Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppressionMolecular Immunology, 2008
- Enhancing SIV-specific immunity in vivo by PD-1 blockadeNature, 2008
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infectionNature Immunology, 2008
- Up on the tightrope: natural killer cell activation and inhibitionNature Immunology, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Nature Immunology, 2003